文献速递泌尿生殖技术与安全PETCT

PSMA-RADS在改善前列腺癌评估与管理中的应用

PSMA-RADS to improve evaluation and management of prostate cancer.
PubMed 文献 · Abdom Radiol (NY) · 2024-12-20

本文介绍PSMA-RADS 2.0这一结构化判读标准,用于评估PSMA PET/CT扫描中病灶的前列腺癌累及可能性。该标准2023年更新,新增PSMA-RADS 5T分类用于治疗后的转移灶,旨在提高诊断准确性和治疗规划的一致性。

要点

  • PSMA-RADS 2.0按病灶前列腺癌累及可能性进行结构化分类,便于纵向监测。
  • 2023年更新新增PSMA-RADS 5T分类,专门用于治疗后的转移灶。
  • PSMA表达并非前列腺癌细胞独有,标准化判读标准对一致性沟通至关重要。

核心结论

  • PSMA-RADS提供结构化方法评估PSMA PET/CT扫描,按病灶前列腺癌累及可能性分类,改善纵向监测并指导管理策略。

研究设计与样本

  • 本文为以病例为基础的教学性综述,介绍PSMA-RADS判读系统及其2023年更新的2.0版本。
  • PSMA PET/CT已成为前列腺癌管理的关键手段,具有更优的诊断准确性。
  • FDA批准的诊疗一体化药物177Lu-PSMA-617进一步提升了PSMA PET/CT成像的重要性。

诊断标准与关键数值

  • PSMA-RADS 2.0按病灶前列腺癌累及可能性进行分类,新增PSMA-RADS 5T分类用于治疗后的转移灶。

临床应用与阅片要点

  • 放射科医生通过病例学习熟悉PSMA-RADS,可提高诊断准确性和治疗规划能力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) / computed tomography (CT) has become essential in managing prostate cancer, offering superior diagnostic accuracy. The introduction of the U.S. Food and Drug Administration (FDA)-approved theranostic agent (177Lutetium-PSMA-617) has further enhanced the significance of PSMA PET/CT imaging. Despite its benefits, PSMA-PET/CT is not without challenges, as PSMA expression is not exclusive to prostate cancer cells. Therefore, standardized interpretation criteria are necessary for consistent and reliable communication among physicians. The PSMA- reporting and data system (RADS) provides a structured approach for assessing PSMA-PET/CT scans. Updated in 2023, PSMA-RADS 2.0 addresses previous limitations and introduces a new category, PSMA-RADS 5T, for treated metastases. This system categorizes lesions based on their likelihood of prostate cancer involvement, improving longitudinal monitoring and guiding management strategies. By familiarizing radiologists with PSMA-RADS through case-based reviews, this primer aims to enhance diagnostic accuracy and treatment planning for patients with prostate cancer.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Rafiei Alavi N, Rahmani M, Gupta A, et al. PSMA-RADS to improve evaluation and management of prostate cancer. Abdom Radiol (NY). 2024. PMID: 39702798. doi:10.1007/s00261-024-04738-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。